Q32 Bio Inc.

What they do

{ "headline": "Q32 Bio Inc. is a clinical-stage biotechnology company developing biologics for alopecia areata (AA) and other autoimmune and inflammatory diseases, with no products approved for sale.", "what_they_do": "Q32 Bio is developing bempikibart (ADX-914), a fully human anti-IL-7 receptor alpha antagonist monoclonal antibody designed to block IL-7 and TSLP signaling and re-regulate adaptive immune function. Bempikibart has completed two Phase 2a trials: SIGNAL-AA Part A in severe and very severe alopecia areata and SIGNAL-AD in atopic dermatitis. The company is also advancing ADX-914-XL, a half-life extended anti-IL-7R antibody sharing bempikibart's mechanism, in preclinical development. Q32 Bio has no products approved for commercial sale and has not generated any product revenue.", "revenue_drivers": [ { "name": "Product revenue", "detail": "None. The company has no products approved for commercial sale and has not generated any product revenue to date, and annual revenue was $0.00 in 2024." }, { "name": "Bempikibart (ADX-914)", "detail": "Lead clinical candidate; no product revenue. Value depends on the ongoing SIGNAL-AA Part B trial and a planned registration-directed program in severe and very severe AA." }, { "name": "ADX-914-XL", "detail": "Half-life extended anti-IL-7R antibody in preclinical development; a pipeline-stage asset with no near-term revenue." }, { "name": "Other revenue", "detail": "Reported annual revenue of $53.7M in 2025 and $34.0M in 2021 is not tied to product sales in the excerpts; the 10-K describes the company as having no products for sale and no product revenue." } ], "recent_performance": "In July 2026 the company reported positive 36-week topline results from Part B of the SIGNAL-AA Phase 2a trial in 33 patients with severe or very severe AA. Bempikibart showed a mean percent reduction in SALT score from baseline of 35.3% in the prespecified modified intent-to-treat analysis, with 40.0% of mITT patients and 30.3% of all enrolled (ITT) patients achieving a SALT-20 response at Week 36. Bempikibart was generally well-tolerated with no new safety signals and a favorable PK, PD, and anti-drug antibody profile. As of June 30, 2026, cash and cash equivalents were $106.3 million, and the company completed a $200 million public offering in July 2026." }, "strategy": "Q32 Bio intends to initiate a registration-directed program evaluating bempikibart in severe and very severe alopecia areata in the first half of 2027, subject to planned regulatory discussions later in 2026. Additional 36-week data and initial 52-week off-drug findings are to be presented at a medical meeting in the second half of 2026. The company is also evaluating expansion into broader alopecia areata populations and additional immunology and inflammation indications where IL-7 and TSLP signaling play a role. In parallel, it is advancing ADX-914-XL, a half-life extended development candidate with the same mechanism of action as bempikibart. Management states the July 2026 public offering proceeds combined with existing cash are expected to fund operations through Phase 3 topline results from the planned registration-directed program." , "risks": [ { "title": "No products or product revenue", "detail": "The company has no products approved for commercial sale, has not generated any product revenue, and may never become profitable without additional funding." }, { "title": "Dependence on bempikibart", "detail": "The business is substantially dependent on the success of bempikibart, which is in early-stage development and may fail or be delayed." }, { "title": "Need for additional capital", "detail": "Q32 Bio will require substantial additional capital and, if unable to raise it on acceptable terms, may have to delay, reduce, or eliminate clinical trials or development programs." }, { "title": "Licensed intellectual property", "detail": "Rights to develop and commercialize product candidates are subject to third-party license agreements; failure to comply or termination of those agreements could cause loss of important license rights." } ], "outlook": "Management expects to hold planned regulatory discussions later in 2026 and to initiate a registration-directed program for bempikibart in severe and very severe AA in the first half of 2027. Additional SIGNAL-AA Part B 36-week data and initial 52-week off-drug results are expected at a medical meeting in the second half of 2026. Enrollment and dosing in the SIGNAL-AA Part B open-label extension remain ongoing. The company states that cash as of June 30, 2026 plus July 2026 offering proceeds are expected to fund operations through Phase 3 topline results from the planned registration-directed program." , "key_facts": [ { "label": "Ticker / exchange", "value": "QTTB on The Nasdaq Capital Market" }, { "label": "Lead candidate", "value": "Bempikibart (ADX-914), anti-IL-7R alpha antibody" }, { "label": "Cash and equivalents", "value": "$106.3M as of June 30, 2026" }, { "label": "SIGNAL-AA Part B enrollment", "value": "33 patients; 36-week topline reported July 2026" } ] }